What are the risks of serotonin syndrome when using MDMA and SSRIs together?
Zenodo (CERN European Organization for Nuclear Research) July 7, 2026 preprint DOI: 10.5281/zenodo.21242234 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
There is limited or indirect evidence suggesting that combined use of MDMA and SSRIs may increase the risk of serotonin syndrome. Healthcare providers should be vigilant in identifying symptoms and discourage such drug interactions.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |